Login to Your Account


Manufacturing, specificity challenges, also enormous potential for T-cell therapies

By Karen Pihl-Carey
Staff Writer

Tuesday, October 7, 2014

SAN FRANCISCO – Displaying two radiographs side by side on a screen, Kite Pharma Inc.'s chief medical officer, David Chang, illustrated the profound potential of T-cell therapies in treating advanced cancers.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription